17 December 2020 16:00 GMT
Transaction by Person Discharging Managerial Responsibilities
Disclosure under Article 19 of the EU Market Abuse Regulation
AstraZeneca PLC (the Company) announces that, on 16 December 2020, it was notified of transactions in the Company's Ordinary Shares of $0.25 each (Ordinary Shares) and American Depositary Shares (ADSs) by certain Persons Discharging Managerial Responsibilities (PDMRs) of the Company as set out below. Two ADSs are equivalent to one Ordinary Share.
|
PDMR |
Position |
Nature of the transaction |
Quantity |
Price |
|
Michel Demaré |
Non-Executive Director |
Purchase of Ordinary Shares |
1,300 |
GB£76.80 |
|
Euan Ashley |
Non-Executive Director |
Purchase of ADSs |
700 |
US$51.52 |
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
Name
|
Michel Demaré |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Non-Executive Director |
||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a)
|
Name
|
AstraZeneca PLC |
||||
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
||||
|
b)
|
Nature of the transaction
|
Purchase of AstraZeneca PLC Ordinary Shares |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
||||
|
e)
|
Date of the transaction
|
16 December 2020 |
||||
|
f)
|
Place of the transaction
|
XLON |
||||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
Name
|
Euan Ashley |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Non-Executive Director |
||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a)
|
Name
|
AstraZeneca PLC |
||||
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
AstraZeneca PLC American Depositary Shares
CUSIP: 046353108 |
||||
|
b)
|
Nature of the transaction
|
Purchase of AstraZeneca PLC American Depositary Shares |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
||||
|
e)
|
Date of the transaction
|
16 December 2020 |
||||
|
f)
|
Place of the transaction
|
XNAS |
||||
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
